Background
==========

This study aims to detect Nevirapine (NVP) side effects among patients started with lead in dose at initiation of Anti Retroviral Therapy (ART) with CD4 count \>250 cells/mm^3^in female and CD4 count \>400 cells/mm^3^in male.

Methods
=======

Close monitoring was conducted for the detection of NVP based side effects among ART - naïve patients initiated on CD4 count \>250 cells/mm^3^among women and CD4 count \> 400 cells/mm^3^are the study target at Centre of Excellence (CoE), ART Centre, B. J. Medical College, Civil Hospital, Ahmedabad, Gujarat, India.

Results
=======

Total 5060 patients were initiated ART during the period of may 2005 to may 2009 at the institute. Among this 3647 (72%) were initiated with NVP lead in dose as per the Indian National ART Guidelines, Table [1](#T1){ref-type="table"}.

  Parameter                                                                    Outcome            
  ---------------------------------------------------------------------------- ------------------ --------------
  NVP lead in dose initiated patients                                                             3647 (n)
                                                                               Male               2408(66.02%)
                                                                               Female             1239(33.97%)
                                                                                                  
  Male with CD4 \>400 cells/mm^3^and initiated NVP lead in dose (n = 2408)     47(1.95%)          
                                                                                                  
  Female with CD4 \>250 cells/mm^3^and initiated NVP lead in dose (n = 1239)   112(9.03%)         
                                                                                                  
  NVP induced Rash                                                             Male (n = 47)      0
                                                                               Female (n = 112)   5(4.46%)
                                                                                                  
  NVP induced Hepatitis                                                        Male (n = 47)      1(2.12%)
                                                                               Female (n = 112)   0
                                                                                                  
  Male with CD4 \<400 cells/mm^3^and initiated NVP lead in dose (n = 2408)     1629(67.64%)       
                                                                                                  
  Female with CD4 \<250 cells/mm^3^and initiated NVP lead in dose (n = 1239)   838(67.63%)        
                                                                                                  
  NVP induced Rash                                                             Male (n = 1629)    19(1.16%)
                                                                               Female (n = 838)   15(1.78%)
                                                                                                  
  NVP induced Hepatitis                                                        Male (n = 1629)    5(0.30%)
                                                                               Female (n = 838)   2(0.23%)

Discussion
==========

Skin Rash was recovered on substituting with another NNRTI- Efavirenz (EFV) and the treatment was well tolerated. Hepatitis was managed with substitution to EFV and close follow-up on ALT and AST. Though western literature has a black box warning for use of NVP, this data shows if closely monitored it could be given at resources limited settings with CD4 counts \>250 cells/mm^3^in females and \>400 cells/mm^3^males. Nevirapine is cost effective molecule compared to Efavirenz and when given in such conditions of higher CD4 need close follow up.
